Quantbot Technologies LP Zentalis Pharmaceuticals, Inc. Transaction History

Quantbot Technologies LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$18.07 - $25.6 $175,279 - $248,320	9,700 Added 248.72%	13,600 $273,000
Q3 2022 Nov 07, 2022	SELL	$20.23 - $31.73 $75,801 - $118,892	-3,747 Reduced 49.0%	3,900 $84,000
Q2 2022 Aug 09, 2022	SELL	$17.91 - $52.25 $4,531 - $13,219	-253 Reduced 3.2%	7,647 $214,000
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $296,964 - $577,716	7,142 Added 942.22%	7,900 $364,000
Q4 2021 Feb 11, 2022	BUY	$66.92 - $84.79 $50,725 - $64,270	758 New	758 $63,000
Q3 2021 Nov 09, 2021	SELL	$46.83 - $73.5 $4,823 - $7,570	-103 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$37.41 - $62.25 $3,853 - $6,411	103 New	103 $5,000

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $166M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.